Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...

A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...

The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) has developed an indigenous occlusion device for the non-surgical closure of Atrial Septal Defect (ASD), a congenital ...

NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...

February 7, 2008 (Chicago, IL) - Doctors and regulators concerned about the spike in off-label patent foramen ovale (PFO) closure procedures now have some numbers to fall back on. A research letter ...

An innovative trans-catheter device closure of a secundum Atrial Septal Defect (ASD) or a hole in the centre of the wall between the two upper chambers of the heart in a 16-month-old baby girl Ovi has ...

A broad spectrum of procedures ranging from basic diagnostic cardiac catheterization to transcatheter closure of atrial septal defects (ASDs) has progressed to the point where such techniques are ...

Percutaneous closure can be described as a less-invasive surgical procedure used to treat patients with atrial septal defect (ASD) or patent foramen ovale (PFO). Since the utilization of percutaneous ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...